Biognosys Launches Spectronaut 16 and Presents Major Advances to its Proteomics Platforms at the ASMS 2022 Annual Conference
26.5.2022 15:00:00 EEST | Business Wire | Press release
Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced the company is attending the American Society for Mass Spectrometry (ASMS) Annual Conference from June 5 to June 9 in Minneapolis (Minnesota, USA) where the company will launch Spectronaut 16 and present major scientific and technological advances of its proprietary proteomics research services.
Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration. In addition, their team of scientific experts will be present at booth #306 to answer questions and demo software.
Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly for proteomics data analysis and drug and biomarker discovery.
“Our major contribution to the ASMS scientific program once again highlights our relentless commitment to innovation in mass spectrometry-based proteomics,” said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys. "With our Spectronaut 16 release, we continue to drive progress in DIA proteomics, and our TrueDiscovery and TrueTarget presentations demonstrate the utility of our research platforms for drug discovery and clinical trials.”
Spectronaut 16 provides the deepest proteome coverage available
At this year’s ASMS conference, Biognosys will commemorate the 10th anniversary of its flagship software, Spectronaut, with the launch of Spectronaut 16 in two breakfast seminars. The first seminar, “Spectronaut 16: Reaching New Depths in DIA Proteomics with AI”, takes place on June 6 with presentations from Oliver Bernhardt (Biognosys) and guest speaker Birgit Schilling (The Buck Institute). The second seminar, “Spectronaut: The Best Ally for Your Visionary Projects,” on June 8 features guest speakers Jesper V. Olsen (University of Copenhagen) and Yansheng Liu (Yale University School of Medicine).
Further, Biognosys will present three posters, demonstrating the significant improvements in Spectronaut 16 for direct searches on complex DIA data with reduced analysis time, deep-learning-based scoring in a dia-PASEF analysis pipeline, and score identifications with minimal computation time through the neural network DeepXIC that uses ion chromatograms to score for identifications.
Biofluid biomarker discovery in neurodegenerative and chronic autoimmune diseases with TrueDiscovery
Biofluids can often be collected less invasively and more frequently than tissue samples to provide an overview of what is happening in the organism. At ASMS, Biognosys will highlight the clinical utility of its proprietary proteomics platform TrueDiscovery™ for unbiased biomarker discovery in biofluids in two oral presentations on June 6. The first oral presentation explores proteomics data collected from CSF and plasma samples in a clinical study in collaboration with Johns Hopkins University, aimed at detecting actionable biomarkers for Alzheimer’s disease (AD). The study identified several proteomic biomarkers for healthy and pathological individuals, some of which were shared in both sample types. The second talk will show data from a clinical study in collaboration with Takeda on Systemic Lupus Erythematosus (SLE). Novel as well as previously reported biomarkers have been identified in plasma and could be used to stratify the disease state. Moreover, disease-specific biomarkers could be described to differentiate patients with renal involvement.
Drug target identification in oncology with TrueTarget
In a collaboration between Biognosys, AstraZeneca, and Pelago Bioscience, proteomics was used to identify and characterize the protein targets of a kinase inhibitor compound across the CDK family. At ASMS, Biognosys will present data demonstrating the performance of its proprietary TrueTarget platform to reveal the target and binding affinity of the drug and highlight complementarities with two other proteomics-based techniques. The presentation builds further on earlier data from this study, published in ACS Chemical Biology.
Visit biognosys.com/asms2022 for a complete overview of Biognosys’ presence at ASMS.
About Spectronaut®
Spectronaut is Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics.
The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit spectronaut.com.
About TrueDiscovery™
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced patented Data Independent Acquisition (DIA)-based protein quantification technology co-invented by tech pioneers at Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.
About TrueTarget™
The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.
TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.
The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio.
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut®. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005037/en/
Contact information
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OKX Sets a New Standard for Account Protection with OKX Shield22.9.2026 13:30:00 EEST | Press release
OKX, a leading global cryptocurrency exchange and onchain technology company with more than 150 million customers worldwide, today launched OKX Shield. OKX Shield is an integrated security product suite combining sophisticated safeguards, visible protection status and the potential for customers to be paid back up to €500,000 following a third-party account-takeover. Account takeover fraud is a challenge for all financial businesses to protect customers against, with billions lost every year in Europe. The most recent EBA and ECB data shows €4.2 billion in payment fraud across Europe in 2024, which was up from €3.5 billion in 2023. Customers are being targeted directly, with attempts to compromise their accounts across financial platforms. OKX Shield brings together account-security enhancements with a new protection program, providing up to €500,000. Customers who activate OKX Shield and maintain the required safeguards can be made whole if an unauthorized third party takes over their
Infobip Predicts 7.3 Billion Black Friday and Cyber Monday Interactions as AI Reshapes the 2026 Shopping Season22.9.2026 13:26:00 EEST | Press release
Global AI-first cloud communications platform Infobip predicts more than 7.3 billion customer interactions across Black Friday and Cyber Monday 2026, as AI and conversational channels transform how consumers discover products, receive offers and access support. New Infobip research also reveals that 63.2% of consumers have used an AI assistant or chatbot while shopping during the past 12 months. Black Friday is no longer a single shopping event. Infobip’s research shows that the shopping season now begins weeks earlier and continues through the entire customer journey. Nearly six in ten respondents will have started holiday shopping by early November, while only 19% wait until Black Friday week itself. This extended shopping window is creating new pressure for retailers to engage customers earlier, with better timing, more relevant offers and frictionless support across the channels consumers already use. AI is becoming a central part of that journey. According to the research, 63.2% o
Aurora Solar Expands Beyond Solar, Adds Home Electrification, More Flexible Financing, and a Growing International Footprint22.9.2026 13:00:00 EEST | Press release
Aurora Solar today announced platform updates across the U.S., U.K., and Europe, reaching beyond solar + storage and into the electrified home. The 2026 Aurora Solar Snapshot found that 71% of U.S. homeowners are interested in solar. These advances help turn that interest into action, giving installers and homeowners flexible financing, accurate proposals, a low-pressure way to buy, and insight into the potential for an electrified home. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922783110/en/ The updates include: Home electrification integrated into proposals: Empowers sales pros to seamlessly quote energy optimizations like HVAC, EV chargers, and battery storage in the same sales proposal as solar. Available to U.S. installers. Prepaid leases and financing flexibility: Provides sales pros with more financing options, from prepaid leases to prepaid PPAs and beyond, to put solar in reach for more customers. Available
Philip Morris International Publishes Inaugural Taskforce on Nature-related Financial Disclosures Report22.9.2026 12:00:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today published its inaugural Taskforce on Nature-related Financial Disclosures (TNFD) Report, providing shareholders and other stakeholders with its most comprehensive assessment to date of nature-related dependencies, impacts, risks, and opportunities (DIROs) across the company’s global value chain. As an early adopter of the TNFD recommendations, PMI’s TNFD Report supports the company’s efforts to sharpen its understanding of how natural capital considerations influence business resilience and decision-making over time, while contributing to emerging practices in nature-related disclosure. Nature is one of the six strategic priorities that define PMI’s Value Plan 2030+, the company’s framework for long-term sustainable value creation, alongside Consumers, Circularity, Climate, Our Workforce, Workers in Our Value Chain. The TNFD Report follows the release of PMI’s 2025 Climate Transition Plan, prepared in line with the TCFD framework,
ROSHN Group Expands Foreign Real Estate Ownership Opportunities Across Saudi Arabia22.9.2026 10:00:00 EEST | Press release
ROSHN Group, Saudi Arabia’s leading master developer and a PIF company, is supporting a new chapter for international participation in the Saudi real estate market, as the Kingdom’s regulations governing non-Saudi property ownership create new opportunities for eligible international buyers and investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922356820/en/ ROSHN Group offers world-class living and investment opportunities, including SEDRA Curated Collection in Riyadh (Photo: AETOSWire) Thousands of non-Saudi buyers have registered interest with ROSHN Group since the regulatory updates, reflecting the growth and diversification of the Kingdom’s real estate sector by attracting new sources of demand and investment, while complementing the continued delivery of homes and communities for Saudi citizens. For ROSHN Group, this creates an opportunity to broaden access to its growing portfolio while expanding housing sup
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom